Asset
Ralzapastotug
Arcus Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04772989 | phase1 | completed | 2021-03-19 | 2025-08-25 | Arcus Biosciences, Inc. | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies |
FDA applications (0)
This company has no applications containing this asset.